CSL Behring

CSL Behring

CSL Behring logo

CSL Behring is a global biotechnology company that specializes in the development and delivery of innovative therapies for people with rare and serious diseases. The company is a leader in the field of plasma protein biotherapeutics and is dedicated to improving the quality of life for patients worldwide.

History

CSL Behring was formed as a result of the merger between CSL Limited and Aventis Behring in 2004. CSL Limited, an Australian company, acquired Aventis Behring, a division of the French pharmaceutical company Aventis, to expand its global presence in the biopharmaceutical industry. The merger combined CSL's expertise in plasma fractionation with Aventis Behring's extensive product portfolio.

Products and Services

CSL Behring offers a wide range of products and services, primarily focused on the treatment of rare and serious conditions. These include:

• Immunoglobulins: Used to treat immune deficiencies and autoimmune diseases.
• Coagulation factor concentrates: For the treatment of bleeding disorders such as hemophilia.
• Albumin: Used in critical care settings to treat shock and burns.
• Alpha-1 proteinase inhibitor: For the treatment of Alpha-1 antitrypsin deficiency.

Research and Development

CSL Behring invests heavily in research and development to advance the science of biotherapeutics. The company focuses on discovering new therapies and improving existing ones to address unmet medical needs. CSL Behring's R&D efforts are supported by a global network of research facilities and collaborations with leading academic institutions.

Global Presence

CSL Behring operates in over 30 countries and has manufacturing facilities in the United States, Germany, Switzerland, and Australia. The company's global reach allows it to deliver life-saving therapies to patients around the world.

Corporate Social Responsibility

CSL Behring is committed to corporate social responsibility and actively engages in initiatives that support patient communities, promote health and wellness, and protect the environment. The company collaborates with patient advocacy groups and healthcare professionals to improve access to therapies and enhance patient care.

Related Pages

• Biotechnology
• Plasma (blood)
• Pharmaceutical industry
• Rare disease